Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 241 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer December 15, 2023 FDA Approves New Interchangeable Biosimilar to Pertuzumab December 3, 2025 NICE doesn’t recommend olaparib for patients with certain prostate cancers September 13, 2022 ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk... October 27, 2020 Load more HOT NEWS Coronavirus reports – Part 7: “I’m more concerned about the second... Cancer target missed for 55,000 patients over 6 years Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients... Veteran Dresses As Captain America & Brings Joy To Children In...
